Midostaurin for treating advanced systemic mastocytosis: Appraisal consultation

In DRAFT guidance, NICE does not recommend midostaurin for treating advanced systemic mastocytosis (aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasms and mast cell leukaemia) in adults.

National Institute for Health and Care Excellence